摘要
利妥昔单抗是针对B淋巴细胞表面CD20抗原的单克隆抗体。研究表明,利妥昔单抗为恶性肿瘤以及自身免疫性疾病的治疗带来了希望。近年来,利妥昔单抗已被用于治疗多种免疫相关性肾脏疾病,如难治性微小病变型肾病、局灶节段性肾小球硬化肾炎、特发性膜性肾病、ANCA相关性血管炎肾损伤、狼疮性肾炎等。本文就利妥昔单抗在免疫相关性肾脏疾病中的应用作一综述,为相关肾脏疾病的临床治疗提供依据。
Rituximab is a monoclonal antibody targeting the CD20 antigen on the surface of B lymphocytes.Studies have shown that rituximab has brought hope for the treatment of malignant tumors and autoimmune diseases.In recent years,its application has expanded to immune-related renal diseases,including refractory minimal change nephrotic syndrome,focal segmental glomerulosclerosis,idiopathic membranous nephropathy,ANCA-associated vasculitis-induced renal injury,and lupus nephritis.This article reviews the application of rituximab in immune-related kidney diseases,providing a basis for the clinical treatment of related kidney diseases.
作者
郭蕊
叶寅寅
GUO Rui;YE Yinyin(Department of Nephrology,Yijishan Hospital,Wannan Medical College,Wuhu 241001,China)
出处
《沈阳医学院学报》
2025年第3期293-297,共5页
Journal of Shenyang Medical College
基金
2023年度省高校重点研究项目(No.2023AH051759)
优秀青年科研项目(No.2023AH030107)
弋矶山医院人才引进项目(No.YR202213)。
